FTC case against insulin price gouging halted after commissioners fired by Trump
A Federal Trade Commission (FTC) case against insulin price gouging has come to a screeching halt after two Democratic commissioners were fired by President Donald Trump.
On March 31, the FTC stayed its suit against pharmacy middle managers, called pharmacy benefit managers (PBMs). Government investigations, including one by the FTC, have pointed to PBMs, as behind at least part of the high prices.
The FTC said in its order that the case couldn’t move ahead because the remaining two Republican commissioners had recused themselves.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleFTC secures $145 Million in settlements over misleading health insurance sales and data practices
Two major health insurance brokers will pay a combined $145 million to resolve Federal Trade Commission allegations that they misled millions of consumers and mishandled personal data, the agency announced Thursday.
-
News BriefTrump’s firing of FTC commissioner violated federal law, court finds
The firing of a Democrat commissioner of the U.S. Federal Trade Commission by President Donald Trump was illegal, according to a federal judge’s ruling last week.
-
News BriefFTC pushes back timeline for ‘Click to Cancel’ Rule, raising compliance questions
The Federal Trade Commission was set to begin enforcement of the “click to cancel” rule on May 14, but a new announcement from the agency pushed that date to July 14. As is the case with many of the regulatory decisions by the Trump administration, it’s unclear whether the agency ...
More from Regulatory Enforcement
-
News BriefFTC puts GM’s puts connected vehicle data practices under compliance spotlight
The U.S. Federal Trade Commission finalized its order against General Motors and its OnStar subsidiary over the improper usage of geolocation and driving behavior data of drivers.
-
ArticleKaiser plans pay $556M to settle Medicare upcoding allegations
Kaiser Health affiliates have agreed to pay more than $556 million to settle allegations originally made by whistleblowers that they ignored compliance department warnings and unlawfully reworked diagnoses for Medicare patients in order to receive higher payments from the federal government.
-
ArticleU.K. regulators move to curb AI nudification tools as scrutiny of Grok grows
The U.K. government’s spat with Big Tech owner Elon Musk over the more risque capabilities of X’s AI assistant Grok has exposed more cracks than the chatbot was ever meant to.